Accelerate Diagnostics, Inc.: Accelerate Diagnostics to Present Data at European Congress

TUCSON, Ariz., 2016-04-10 22:02 CEST (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. ("Accelerate") announced today it will present data related to the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures while attending the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit were formerly the Accelerate ID/AST System and Blood Culture Assay Kit.

The aforementioned data can be found in the investor presentation posted at ir.axdx.com.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant organisms. For more information about the company and its products visit www.acceleratediagnostics.com.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, our projections as to when certain key business milestones may be achieved, including initiation of the trial intended to support marketing authorization by the FDA of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the commercial launch of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for positive blood cultures, the potential of our technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016. In addition, the company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

Media Contact: Andrew Chasteen [phone] [e-mail]

Investor Contact: Laura Pierson [phone] [e-mail]